Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
which increases SUMOylation of SERCA2a
CAS Number: 98319-26-7
1-2H3/t25-
Asciminib is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia
trans-Trimethoxyresveratrol 9596 which increases SUMOylation of SERCA2aTrans Trimethoxyresveratrol is a derivative of Resveratrol (RSV),and it may be a more potent anti inflammatory, antiangiogenic and vascular disrupting agent when compared with resveratrol. In vitro: The in vitro study of resveratrol and trans Trimethoxyresveratrol showed rather weak cytotoxic effects on three cancer cell lines (HepG2, MCF 7, and MDA MB 231), which contradicted a previous study reporting that resveratrol inhibited MCF 7 cells with an
US$ 15.00
US$ 19.00
US$ 27.50
US$ 15.99